Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Baljinder Singh

Neurology Lewiston, NY Medical Doctor

NPI 1356539415 CMS profile 288853

5300 Military Rd, Lewiston, NY 14092

Open in the dashboard

General payments

$78,933

1,214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Baljinder Singh of Lewiston, NY is reported in the CMS Open Payments database as having received $78,933 across 1,214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,428 250
2024 General $12,701 210
2023 General $10,558 194
2022 General $12,892 205
2021 General $14,853 203
2020 General $15,411 109
2019 General $1,090 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Baljinder Singh
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Baljinder Singh were reported at $11,428. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Baljinder Singh Neurology median Middle half National median
2019 $1,090 $474 $118–$2,177 $163
2020 $15,411 $367 $82–$2,309 $114
2021 $14,853 $438 $104–$2,547 $132
2022 $12,892 $442 $103–$2,388 $149
2023 $10,558 $464 $119–$2,312 $160
2024 $12,701 $468 $119–$2,323 $164
2025 $11,428 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $36,202 150 payments
  2. Allergan Inc. $15,649 51 payments
  3. LivaNova USA, Inc. $2,845 44 payments
  4. Abbott Laboratories $2,539 24 payments
  5. UCB, Inc. $2,212 94 payments
  6. Teva Pharmaceuticals USA, Inc. $1,608 57 payments
  7. TG Therapeutics, Inc. $1,366 37 payments
  8. Biogen, Inc. $1,257 70 payments
  9. SK Life Science, Inc. $1,095 36 payments
  10. Pfizer Inc. $948 46 payments
  11. Other $13,212 605 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,255 24 payments
  2. Food and Beverage $27,752 1,157 payments
  3. Travel and Lodging $4,633 21 payments
  4. Education $293 12 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $32,504 96 payments
  2. UBRELVY Neuroscience $13,773 39 payments
  3. QULIPTA $13,674 64 payments
  4. INFINITY $2,128 15 payments
  5. VNS - Sentiva $1,558 5 payments
  6. BRIUMVI $1,366 37 payments
  7. Briviact $1,029 52 payments
  8. Rystiggo $745 25 payments
  9. AUSTEDO $732 24 payments
  10. VUMERITY $707 43 payments
  11. Other $20,161 907 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,093

Median for Neurology: 833

Drug cost

$226,907

Median for Neurology: $202,670

Branded share of claims

18.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 25 $152,338
Ubrelvy Ubrogepant Brand 28 $44,101
Nurtec Odt Rimegepant Sulfate Brand 12 $12,073
Levetiracetam Generic 113 $4,028
Gabapentin Generic 248 $3,024
Memantine Hcl Generic 114 $1,791
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 22 $1,260
Carbidopa-Levodopa Carbidopa/Levodopa Brand 80 $1,151
Pregabalin Generic 29 $1,088
Oxcarbazepine Generic 18 $1,022

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$54,696

Medicare's payments for the services billed

Medicare patients

229

Average age 70

Services billed

487

127 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 38%
Ischemic heart disease 35%
Depression 35%
COPD 28%
Chronic kidney disease 25%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$5,407 28 —
BRIUMVI
$605 — —
Rystiggo
$402 — —
OCREVUS
$228 — —
Leqembi
$225 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

1,214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record